AngioDynamics loses antitrust jury verdict against C.R. Bard in PICC market

ANGIODYNAMICS INC

Jury found Bard did not unlawfully restrain competition in U.S. PICC market following two-week trial in N.D.N.Y.
AngioDynamics 'disappointed' with outcome, considering appeal.
Verdict covers percutaneously inserted central catheters (PICCs), a vascular access device.
No monetary damages or financial impact disclosed in filing.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.